Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS3416530 A
Type de publicationOctroi
Date de publication17 déc. 1968
Date de dépôt2 mars 1966
Date de priorité2 mars 1966
Numéro de publicationUS 3416530 A, US 3416530A, US-A-3416530, US3416530 A, US3416530A
InventeursRichard A Ness
Cessionnaire d'origineRichard A. Ness
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Eyeball medication dispensing tablet
US 3416530 A
Images(2)
Previous page
Next page
Description  (Le texte OCR peut contenir des erreurs.)

Dec. 17, 1968 R. A. NESS 3,416,530

EYEBALL MEDICATION DISPENSING TABLET Filed March 2, 1966 2 Sheets-Sheet l INVENTOR.

R/cHARo A. Nsss BY AT TORNE Y5 Dec. 17, 1968 Filed March 2, 1966 FIG. 3

R. A. NESS EYEBALL MEDICATION DISPENS ING TABLET 2 Sheets-Sheet 2 'AT TORNE Y5 United States Patent 3,416,530 EYEBALL MEDICATION DISPENSING TABLET Richard A. Ness, Fergus Falls, Minn. 56537 Filed Mar. 2, 1966, Ser. No. 531,311 7 Claims. (Cl. 128260) This invention relates generally to the treatment of disseases of the eye, and more particularly, to novel means for dispensing medication to the human eyeball.

At the present time, in the treatment of eye diseases, such as glaucoma, medication is applied to the cornea of the eye in liquid or ointment form. In many cases, to be effective, the application of medication to the cornea should be substantially continuous. Such a procedure is highly inconvenient and confining to the patient. At best, the medication is applied at intervals during the day and night. However, the difiiculty with such periodic application is that the eye receives a massive dose at the time of application, and shortly thereafter, substantially all of the medication is washed away by tears, leaving the eye, particularly the cornea thereof, without medication until the next dose is applied.

An important object of this invention is the provision of means whereby medication is applied to the eyeball continuously over an extended period of time.

Another object of this invention is the provision of a medication dispensing device which may be quickly and easily applied to the eyeball, which will dispense medication thereto-at a predetermined rate of speed, and which may be as quickly and easily removed and replaced when the supply of medicament is exhausted.

Still another object of this invention is the provision of a medication dispensing device having means providing a visual indication of the quantity of medicament available to the eyeball.

Yet another object of this invention is the provision of a medication dispensing device which will conform to the curvature of the sclera so as to fit comfortably in the culde-sac of the conjunctiva between the upper eyelid and the eyeball or globe in radially spaced relation to the cornea, and disposed in the path of tear flow to the cornea, whereby to be responsive to flow of tears to dispense medicament thereto.

To the above ends, I provide a medication dispensing tablet-like body of concavo-convex section and of flexible material and having a smooth curved outline, the concave inner surface of said body having a generally spherical radius conforming substantially to the radius of the scleral portion of an eyeball, the body containing a supply of medicament and adapted to dispense the medicament to tears during flow of said tears from the lacrimal gland toward the cornea of the eyeball, when the body is applied to the eyeball as set forth. The above, and still further highly important objects and advantages of this invention will become apparent from the following detailed specification, appended cl-aims and attached drawings.

Referring to the drawings, which illustrate the invention, and in which like reference characters indicate like parts throughout the several views:

FIG. 1 is a view partly in front elevation and partly diagrammatic, of a human eye, illustrating the use of the invention;

FIG. 2 is a view partly in vertical section and partly diagrammatic of an eyeball and the upper and lower eyelids associated therewith, showing the placement of the medication dispensing tablet of this invention;

FIG. 3 is a view in top plan of a preferred form of medication dispensing tablet of this invention;

FIG. 4 is a longitudinal section, taken on the line 44 of FIG. 3;

FIG. 5 is a transverse section taken substantially on the line 5-5 of FIG. 3;

FIG. 6 is a view corresponding ot FIG. 3 but showing a modified form of tablet;

FIG. 7 is a view in perspective of means for packaging the tablet of this invention; and

FIG. 8 is an enlarged transverse section, taken on the line 88 of FIG. 7.

Referring particularly to FIGS. 1 and 2, a human eye is shown, more or less diagrammatically, as comprising an eyeball 1, and upper and lower eyelids 2 and 3 respectively, the eyeball 1 being covered for the greater parts of its area by the sclera 4 and at its anterior portion by the cornea 5. The eyelids 2 and 3 are lined with a epithelial membrane or conjunctiva 6 which covers the exposed portion of the eyeball including the cornea 5, that portion covering the cornea being transparent, that portion of the conjunctiva 6 which lines the upper eyelid 2 and the underlying portion of the sclera 4 defining a cul-de-sac 7. Upper and lower eyelashes are indicated at 8 and 9 respectively. Other details of the structure of the eyeball 1 are not directly concerned with the structure of the instant invention, detailed showing and description thereof being omitted in the interest of brevity. The usual lacrimal gland associated with the eyeball 1 is shown by dot and dash lines in FIG. 1 and indicated by the numeral 10.

The preferred embodiment of the invention illustrated in FIGS. l-S, a hollow tablet-like body 11, of concavoconvex cross section, is shown as comprising inner and outer walls 12 and 13 respectively, the walls 12 and 13 being joined at their marginal edge portions and defining a chamber 14 that is filled with medicament 15. The marginal juncture of the walls 12 and 13 is rounded, as indicated at 16 in FIGS. 4 and 5, so as to avoid sharp edges and, in the preferred embodiment of the invention, the

outline of the body 11 is bean-shaped or reniform as shown in FIGS. 1 and 3. Communication between the chamber 14 and the exterior of the body 11 is had through a plurality of capillary openings 17 in the walls 12 and 13, as well as through the joined edges thereof. The marginal edges of the inner and outer walls 12 and 13 may be joined together by any suitable means, such as heat-sealing, gluing or the like. Preferably, the capillary openings 17 are disposed in the areas of the walls 12 and 13 adjacent the marginal edges thereof as shown particularly in FIG. 3.

In order that the body 11 may comfortably fit in the cul-de-sac 7, the overall dimensions of the body 11 are quite small. Preferably, the overall length of the body 11 is approximately fifteen millimeters, the width thereof intermediate its ends being in the neighborhood of eleven or twelve millimeters. The outer surface 18, which is adapted to be disposed adjacent the sclera, of the inner wall 12 is generally spherical, having a spherical radius of approximately twelve millimeters, corresponding to the radius of the scleral portion of the eyeball. Obviously, the dimensions noted above may be varied in accordance with eyeballs of different sizes. It will be noted, with reference to FIGS. 4 and 5, that the body 11 is of substantially greater thickness at its central portion than at the marginal edge thereof, whereby to define a chamber 14 of a :size to contain sufiicient highly concentrated medication for adequate treatment over at least a days time. Preferably, the maximum thickness of the body 11 is approximately one to one and one-half millimeters. When the body 11, filled with medicament 15, is placed in the cul-de-sac 7, some of the tear liquid flowing from the lacrimal gland 10 to and across the eyeball 1 will enter the chamber 14 through some of the capillary openings 17, and outwardly therefrom through others of the openings 17, carrying with it some of the medicament 15. Responsive to blinking action of the upper eyelid 2, the tear liquid and medicament mixture will flow over the cornea 5 which absorbs the medicament, thus administering a constant supply of medicament to the cornea until the supply within the chamber 14 is exhausted. Normally, the lacrimal gland is disposed just slightly above and posteriorly or rearwardly of the cul-de-sac 7 in a depression of the upper, outer wall of the orbit, not shown. The flow of tears from the lacrimal gland 10 is generally diagonally across the cornea toward the puncta, as is wellknown to those skilled in this art, the general direction of tear flow being indicated by arrows in FIG. 1.

The tablet-like body 11 may be made from any suitable material that is flexible, biologically inert, nonellergenic, insoluble in tear liquid, and chemically compatible with the medicament in the chamber 14. The walls 12 and 13 of the body 11 may be made from polyethylene or any other of well-known synthetic plastic materials having the above-mentioned characteristics. The medicament in the chamber 14 comprises the desired medication for treatment and a soluble or semi-soluble carrier or matrix, the matrix being of any suitable substance such as gum acacia, gum tragacanth, or the like. The matrix serves to hold the medication together during fabrication of the body 11, and operates as a diluent during the medication dispensing operation of the body 11.

Insertion of the body 11 into the cul-de-sac 7 and removal of the body 11 therefrom is a relatively simple and easy operation. The body 11 may be mounted on or grasped by a suitable tool or holder, not shown, but which may include a minute suction cup for engaging the outer Wall of the body 11. The upper eyelid is raised upwardly and outwardly adjacent the outer corner portion of the eye to open the cul-de-sac 7, and the body 11 inserted and released from the holder. The holder may be one of several types commonly used to insert and remove present day corneal contact lenses, artificial eyes and the like.

The present invention contemplates the use of an indicator dye in the medicament 15 to serve as a visual indication as to the supply of medicament within the chamber 14. For this purpose, a small amount of methylene blue or any suitable dye material is used. So that the medicament 15 may be easily seen, the outer wall 13 of the body 11 is preferably transparent, the inner wall 12 being preferably opaque and having a color in substantial contrast to the color of the medicament 15 or indicator dye.

The modified form of the invention illustrated in FIG. 6 comprises a body 19 that is generally elliptical in outline but which in all other respects is identical to the form of body 11 illustrated in FIGS. 1-5. The parts of the body 19 shown in FIG. 6, corresponding to similar parts of the body 11, are indicated by corresponding reference numerals with prime marks added. Thus the outer wall 13 and the marginal edge 16' are provided with capillary openings 17' and it may be assumed that the body 19 is cross-sectionally similar to the body 11, as shown in FIGS. 4 and 5.

A preferred means for packaging the tablets of this invention is shown in FIGS. 7 and 8. A relatively thick sheet-like base member 20 is shown as being formed to provide a plurality of upwardly opening pockets 21, each for reception of a different one of the tablets of bodies 11 or 19, and having upwardly dished bottom walls 22 which substantially fit the overlying inner wall-s of the bodies 11 or 19. A relatively thin cover sheet 23 overlies the base member 20 and is releasably adhered to the top surface thereof intermediate the pockets 21 and adjacent the marginal edge of the base member 20. Preferably, the base member 20 and cover sheet 23 are made from synthetic plastic sheet material, the cover sheet 23 being preferably transparent so that occupancy of any of the pockets 21 by a tablet may be readily seen. Further, when packaging the tablets, it is desirable to introduce a small amount of the medicament into the various pockets 21 to maintain the outer surfaces of the tablets or bodies 11 or 19 in a moist condition for ease of application to the eyeball. Preferably, the upper surfaces of the base member 20 in the pockets 21 are corrugated, knurled, or otherwise roughened, as indicated at 21a, to prevent the liquid in the pockets 21 from causing the bodies 11 to adhere to the pockets 21, and to break any suction therebetween, which might occur if the surfaces of the pockets 21 were smooth.

It will be appreciated that the outline of the tablets 11 or 19 may be of any curved configuration, such as circular, if desired. Further, the capillary openings 17 and 17 need not be necessarily circular as shown. If desired, the walls 12, 13, 12' and 13 may be made from porous material having the characteristics above described in connection with the body 11. Still further, this invention contemplates a body of the shape or shapes above described, which in itself is a solid body, as distinguished from the bodies 11 or 19 which define inner chambers, but which is in itself sufficiently porous to receive the desired amount of medicament and retain the same until the medicament is gradually leached therefrom under the action of tear flow. In such a modification, the body, not shown, may be made from suitable material of a given color, the medication being dyed to a contrasting color, whereby to provide an indication as to the presence or absence of medication in the porous body.

While I have shown and described a preferred form and a single modification of medication dispensing tablet, it will be understood that the same may be produced in other different shapes, such as circular, and that other modifications may be made without departure from the spirit and scope of the invention, as defined in the claims.

What is claimed is:

1. A medication dispensing tablet for a human eyeball, said tablet comprising a cross-sectionally concavoconvex body of flexible material for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and upper eyelid in generally radially spaced relation to the cornea of the eyeball and in the path of flow of tears from the associated lacrimal gland, said body having a curved outline and an inner concave surface, said concave surface having a generally spherical radius substantially equal to that of the outer scleral surface of an eyeball, and a supply of medicament contained within said body, said body being responsive to flow of tears thereover, when the body is applied to the eyeball, to dispense said medicament to the eyeball generally above the cornea, said body being so constructed and arranged that the rate of dispensing said medicament is dependent upon the rate of flow of tears over said body.

2. The medication dispensing tablet defined in claim 1 in which the marginal outline of said body is generally elliptical.

3. The medication dispensing tablet defined in claim 1 in which the marginal outline of said boy is generally bean-shaped.

4. The medication dispensing tablet defined in claim 1 in which said body comprises a pair of inner and outer walls defining a chamber for the medicament, said body having multiple perforations through at least one of said walls, whereby the medicament in said chamber seeps outwardly fro-m said chamber into the tear flow over said body 5. The medication dispensing tablet defined in claim 1 characterized by dye in said medicament for visual indication of the presence of medicament in said body.

5 6 6. The medication dispensing tablet defined in claim References Cited f! which tthe 03ml Of Of saiddbodayl UNITED STATES PATENTS 1s ransparen, 5211 me icarnen incu ing a me 1cm agent and a soluble matrix, characterized by a dye of a 772,028 10/1904 Carpenter 128-260 given color in said medicament, for visual indication of 5 32? 52223;

the presence of medicament in said chamber.

7. The medication dispensing tablet defined in claim 6 l 4 in which the inner one of the Walls of said body is dyed ADELE EAGER Puma), Exammer' to a given color, the dye in said medicament being of a U S C1 X R color substantially different from that of the colored inner 10 Wall. 128261, 268; 16759; 20663.2

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US772028 *13 nov. 190311 oct. 1904George A CarpenterDevice for putting medicine into eyes.
US2347488 *5 avr. 194325 avr. 1944Danz EmilOptical lens
US3302646 *10 janv. 19647 févr. 1967Charles A BehneyApparatus for treating eye infection
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US3618604 *9 juin 19699 nov. 1971Alza CorpOcular insert
US3625214 *18 mai 19707 déc. 1971Alza CorpDrug-delivery device
US3626940 *2 mai 196914 déc. 1971Alza CorpOcular insert
US3630200 *9 juin 196928 déc. 1971Alza CorpOcular insert
US3814097 *24 janv. 19734 juin 1974Ici LtdDressing
US3826258 *7 févr. 197230 juil. 1974Abraham SGradual release medicine carrier
US3828777 *8 nov. 197113 août 1974Alza CorpMicroporous ocular device
US3845770 *5 juin 19725 nov. 1974Alza CorpOsmatic dispensing device for releasing beneficial agent
US3853116 *2 juil. 197310 déc. 1974Investors In Ventures IncImplant methods and devices for influencing body fluids
US3926188 *14 nov. 197416 déc. 1975Alza CorpLaminated drug dispenser
US3995635 *4 nov. 19747 déc. 1976Alza CorporationOcular insert
US4136173 *31 janv. 197723 janv. 1979American Home Products Corp.Mixed xanthan gum and locust beam gum therapeutic compositions
US4136177 *31 janv. 197723 janv. 1979American Home Products Corp.Xanthan gum therapeutic compositions
US4136178 *31 janv. 197723 janv. 1979American Home Products Corp.Locust bean gum therapeutic compositions
US4201210 *28 nov. 19776 mai 1980The United States Of America As Represented By The Secretary Of AgricultureVeterinary ocular ring device for sustained drug release
US4304226 *3 mars 19808 déc. 1981The Procter & Gamble CompanyVaginal contraceptive
US4959217 *22 mai 198625 sept. 1990Syntex (U.S.A.) Inc.Delayed/sustained release of macromolecules
US5270051 *15 oct. 199114 déc. 1993Harris Donald HEnzyme-orthokeratology
US5378475 *21 févr. 19913 janv. 1995University Of Kentucky Research FoundationSustained release drug delivery devices
US5472436 *26 juil. 19945 déc. 1995Fremstad; Daria A.Device for delivering a liquid to an eye
US5626865 *15 oct. 19926 mai 1997Advanced Corneal Systems, Inc.Enzyme-orthokeratology
US5773019 *27 sept. 199530 juin 1998The University Of Kentucky Research FoundationInner core containing an effective amount of a low solubility agent covered by a non-bioerodible polymer coating layer that is permeable to the low solubility agent
US5788957 *12 sept. 19964 août 1998Advanced Corneal Systems, Inc.Enzyme-orthokeratology
US5876438 *2 août 19932 mars 1999Houston Biotechnology IncorporatedPolymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5902598 *28 août 199711 mai 1999Control Delivery Systems, Inc.Sustained release drug delivery devices
US6063116 *24 avr. 199516 mai 2000Medarex, Inc.Modulation of cell proliferation and wound healing
US6132735 *18 sept. 199717 oct. 2000Ista Pharmaceutical, Inc.Reshaping of the cornea to reduce or eliminate refractive errors of the eye.
US6161544 *28 janv. 199819 déc. 2000Keratoform, Inc.Methods for accelerated orthokeratology
US6264971 *4 nov. 199924 juil. 2001Btg International LimitedOcular insert
US63031027 sept. 200016 oct. 2001Kenneth SchlichteVisually determining the residence time of a therapeutically effective amount of one or more medicaments or vaccines; marker formulation having a pigment or dye in combination with a suitable carrier
US633131322 oct. 199918 déc. 2001Oculex Pharmaceticals, Inc.Controlled-release biocompatible ocular drug delivery implant devices and methods
US637597226 avr. 200023 avr. 2002Control Delivery Systems, Inc.Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US64132454 oct. 20002 juil. 2002Alcon Universal Ltd.Sub-tenon drug delivery
US641354012 sept. 20002 juil. 2002Alcon Universal Ltd.For eyes
US641677719 sept. 20009 juil. 2002Alcon Universal Ltd.Ophthalmic drug delivery device
US66699501 juil. 200230 déc. 2003Alcon, Inc.Biocompatible implants for localized delivery of pharmaceutically active agent to the posterior segment of the eye
US669949328 nov. 20012 mars 2004Oculex Pharmaceuticals, Inc.Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US675604917 déc. 200129 juin 2004Bausch & Lomb IncorporatedSustained release drug delivery devices
US675605827 déc. 200129 juin 2004Bausch & Lomb IncorporatedSustained release drug delivery devices with multiple agents
US68087191 juil. 200226 oct. 2004Alcon, Inc.Interior core in well containing active materials; aperture to exterior
US696478127 déc. 200115 nov. 2005Bausch & Lomb IncorporatedFor delivering drug directly to the interior portions of the body of a mammalian organism, such as to the eye
US69869005 nov. 200317 janv. 2006Alcon, Inc.biocompatible implants for delivery of pharmaceutically active agents to the posterior segment of the eye; having a scleral surface, an orbital surface, an injection port on the orbital surface, and a fluid conducting passageway
US699180823 janv. 200231 janv. 2006Bausch & Lomb Inc.Impermeable cup or coating layer is adhered to an uncured suture tab and covered with permeable polymer (polyvinyl acetate); for use in treatment of retinitits and glaucoma
US703360522 déc. 200325 avr. 2006Allergan, Inc.performing an ocular transplant procedure; implanting in the eye a biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer.
US709422612 nov. 200322 août 2006Alcon, Inc.Ophthalmic drug delivery device
US718128724 juil. 200220 févr. 2007Second Sight Medical Products, Inc.Implantable drug delivery device
US752762116 août 20065 mai 2009Second Sight Medical Products, Inc.Implantable drug delivery device
US75632552 mai 200221 juil. 2009Massachusetts Eye And Ear InfirmaryImplantable drug delivery device and use thereof
US758551720 sept. 20048 sept. 2009Macusight, Inc.delivery system contains a solid core of rapamycin or other therapeutic agent
US762190711 mars 200324 nov. 2009Alcon, Inc.Implantable drug delivery system
US762558220 avr. 20071 déc. 2009Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US770871112 nov. 20034 mai 2010Glaukos CorporationOcular implant with therapeutic agents and methods thereof
US776722311 juil. 20053 août 2010Allergan, Inc.biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
US782470415 août 20052 nov. 2010Surmodics, Inc.Controlled release bioactive agent delivery device
US78464683 nov. 20087 déc. 2010Allergan, Inc.Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US79431627 déc. 200617 mai 2011Alcon, Inc.Body having an internal surface for disposing on a target tissue and a well having an opening to the internal surface; inner core with drug containing portion and an expandable material such as hydrogel in the well; delivery drugs such as eliprodil to the eye for example
US797686215 août 200512 juil. 2011Surmodics, Inc.Longitudinal body; polymeric coating of polyalkyl(meth)acrylate and/or aromatic poly(meth)acrylate; and poly(ethylene-co-vinyl acetate); triamcinolone acetonide; drug delivery to eye
US802168029 avr. 200420 sept. 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US803436631 oct. 200711 oct. 2011Allergan, Inc.Poly lactic co-glycolic acid copolymer biodegradable polymer matrix; eye implant infused with ace-inhibitors, endogenous cytokines, agents that influence basement membrane, agents that influence the growth of endothelial cells, adrenergic agonists or blockers; uveitis, macular edema, macular degeneration
US803436912 sept. 200511 oct. 2011Surmodics, Inc.Controlled release bioactive agent delivery device
US803437031 oct. 200711 oct. 2011Allergan, Inc.Active agent dispersed within a biodegradable polymer matrix; bioerodible
US804362831 oct. 200725 oct. 2011Allergan, Inc.biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
US807112030 mars 20066 déc. 2011Allergan, Inc.biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
US80884077 sept. 20073 janv. 2012Allergan, Inc.biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
US809697219 déc. 200317 janv. 2012Johns Hopkins UniversityDevices for intraocular drug delivery
US816785525 août 20041 mai 2012Vista Scientific LlcOcular drug delivery device
US817774730 nov. 201015 mai 2012Alcon Research, Ltd.Method and apparatus for drug delivery
US822227123 mars 200717 juil. 2012Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US824209912 oct. 201114 août 2012Allergan, Inc.Implants and methods for treating inflammation-mediated conditions of the eye
US82469748 avr. 200521 août 2012Surmodics, Inc.Medical devices and methods for producing the same
US82778304 oct. 20112 oct. 2012Forsight Vision4, Inc.Posterior segment drug delivery
US828750422 juil. 201016 oct. 2012Vista Scientific LlcOcular drug delivery device
US82985784 oct. 201130 oct. 2012Forsight Vision4, Inc.Posterior segment drug delivery
US831376315 févr. 200720 nov. 2012Tolmar Therapeutics, Inc.Sustained delivery formulations of rapamycin compounds
US83180701 sept. 201127 nov. 2012Allergan, Inc.Ocular implant made by a double extrusion process
US83488773 mai 20108 janv. 2013Dose Medical CorporationOcular implant with therapeutic agents and methods thereof
US836709712 mai 20105 févr. 2013Santen Pharmaceutical Co., Ltd.Liquid formulations for treatment of diseases or conditions
US83720365 mai 201012 févr. 2013Alcon Research, Ltd.Multi-layer heat assembly for a drug delivery device
US8382725 *20 juin 200926 févr. 2013Michael CampionEye coloring systems
US839900629 janv. 201019 mars 2013Forsight Vision4, Inc.Posterior segment drug delivery
US846993425 janv. 201125 juin 2013Alcon Research, Ltd.Pulsatile peri-corneal drug delivery device
US848605227 déc. 201016 juil. 2013The Johns Hopkins University School Of MedicineReservoir device for intraocular drug delivery
US848696021 juin 201216 juil. 2013Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditions
US84924009 févr. 200723 juil. 2013Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US850698719 août 201113 août 2013Allergan, Inc.Ocular implant made by a double extrusion process
US86233955 août 20117 janv. 2014Forsight Vision4, Inc.Implantable therapeutic device
US86325115 mai 201021 janv. 2014Alcon Research, Ltd.Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
US86370709 févr. 200628 janv. 2014Santen Pharmaceutical Co., Ltd.Rapamycin formulations and methods of their use
US865866724 juin 201325 févr. 2014Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and use
US866363918 août 20084 mars 2014Santen Pharmaceutical Co., Ltd.Formulations for treating ocular diseases and conditions
US867907817 sept. 201225 mars 2014Vista Scientific LlcOcular drug delivery device
US871571228 nov. 20126 mai 2014Forsight Vision5, Inc.Ocular insert apparatus and methods
US876516622 juil. 20131 juil. 2014Novaer Holdings, Inc.Drug delivery devices for delivery of ocular therapeutic agents
US877838112 mars 201315 juil. 2014Allergan, Inc.Ocular implant made by a double extrusion process
US20100004609 *20 juin 20097 janv. 2010Michael CampionEye coloring systems
US20120078362 *18 mai 201029 mars 2012Dose Medical CorporationDrug eluting ocular implant
USB520277 *4 nov. 197417 févr. 1976 Titre non disponible
DE2243986A1 *7 sept. 197229 mars 1973Alza CorpBiologisch abbaubarer augeneinsatz zur verabreichung eines arzneimittels
DE2547378A1 *23 oct. 197529 avr. 1976Searle & CoVorrichtung mit abgeschlossenen mikrokammern zur abgabe eines arzneimittels
EP1982701A219 avr. 200122 oct. 2008pSivida IncSustained Release Drug Delivery Devices, Methods of Use, and Methods of Manufacturing Thereof
EP2329821A129 nov. 20068 juin 2011GlaxoSmithKline LLCTreatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
EP2374451A227 juil. 200612 oct. 2011University of Florida Research Foundation, Inc.Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof
WO1993007840A1 *15 oct. 199229 avr. 1993Advanced Corneal Systems IncEnzyme-orthokeratology
WO1993019707A1 *2 avr. 199214 oct. 1993Bausch & LombOphthalmic article
WO2001030323A2 *19 oct. 20003 mai 2001Donald E Berger JrControlled-release biocompatible ocular drug delivery implant devices and methods
WO2001032140A13 nov. 200010 mai 2001Btg Int LtdOcular insert
WO2011039648A129 sept. 20107 avr. 2011Glaxo Wellcome Manufacturing Pte Ltd.Methods of administration and treatment
Classifications
Classification aux États-Unis424/427, 424/9.1, 206/558, 206/438, 206/564, 351/159.2
Classification internationaleA61K9/00, A61F9/00
Classification coopérativeA61K9/0051, A61F9/0017
Classification européenneA61K9/00M16B, A61F9/00B2